RFK Jr.'s vaccine policies are creating a specific structural problem for the industry: regulatory unpredictability that deters investment in long-term vaccine development projects. The core issue isn't simply Kennedy's skepticism of vaccines—it's that his inconsistent decisions (canceling mRNA contracts, initially rejecting then accepting Moderna's flu vaccine application, preventing FDA publication of favorable safety studies) signal to manufacturers that the U.S. market is no longer a stable place to invest capital. This is distinct from the broader policy debate about vaccine recommendations. A manufacturer planning a $200+ million vaccine development program needs to know the regulatory pathway will be stable across years, and that if they gain FDA approval, the vaccine will actually be recommended and purchased. Kennedy's actions—including his stated intent to potentially overhaul or dismantle the Vaccine Injury Compensation Program—have made both of those assumptions uncertain. The left correctly identifies that this creates an existential threat to vaccine availability (as happened in the 1980s when similar litigation uncertainty drove manufacturers from the market). The right argues these stricter standards are necessary for genuine safety and accountability. What both sides could acknowledge: regulatory certainty matters enormously for a capital-intensive industry. Kennedy's approach has prioritized signaling his commitment to safety concerns over maintaining the stability that enables continued vaccine manufacturing and development. That is a deliberate policy choice with real consequences, not an accidental byproduct.

The most recent development—the May 15 Democratic letter about data suppression—extends the conflict beyond policy disputes into questions of scientific integrity. If Kennedy is indeed preventing FDA staff from publishing favorable safety data, that crosses into direct scientific obstruction rather than policy disagreement. Both sides have incentives to distort this: Democrats want to paint Kennedy as corrupt, Republicans want to defend him as committed to transparency and correcting prior institutional bias. The court records (particularly Judge Brian Murphy's March 2026 ruling finding Kennedy's ACIP overhaul "arbitrary and capricious") provide some neutral evidence that Kennedy prioritized ideological alignment over procedural legality, though judges disagreed about the substance of vaccine policy itself.

What remains genuinely unresolved: whether the U.S. vaccine system was functioning adequately before Kennedy's changes, or whether it had genuine structural problems requiring intervention. The evidence suggests both are partially true—the system had some issues (ACIP member conflicts of interest exist but are heavily regulated), but Kennedy's response has been so destabilizing that it has created a new set of problems (manufacturer exit from the U.S. market, reduced vaccine innovation) worse than the original concern. Upcoming decisions include whether Congress will intervene to restore vaccine injury compensation certainty, whether courts will ultimately overturn Kennedy's ACIP changes permanently, and whether manufacturers' cautious withdrawal from U.S. vaccine markets becomes permanent.

Left outlets use language emphasizing suppression, damage, and danger—ProPublica warned of "catastrophic" consequences, House Democrats accused Kennedy of "censorship," and infectious disease experts invoked existential pandemic threats. Right outlets frame Kennedy's actions as necessary corrections using terms like "radical departure," "transparency," "safety testing," and "restore public trust," assuming Kennedy's premise that prior CDC practice was inadequate. The two sides fundamentally disagree on whether Kennedy is distorting science for ideological reasons or enforcing science-based standards that were previously abandoned.